Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Going private transaction for AHL Services Inc.
Represented the Special Committee of the Board of AHL Services Inc., a provider of outsourced marketing and merchandising support services, in a more
General Media Communications, Inc. v. Heu
Obtained ruling effectively reversing UDRP decision by National Arbitration Forum that GMCI, publisher of Penthouse magazine, had engaged in more
Antitrust review of merger between pharmaceutical companies
Represented a pharmaceutical company before FTC regarding antitrust review of merger with another pharmaceutical company and negotiation of consent more
Cooper v. Sony Music Entertainment Inc., et al.
Defended Sony Music Entertainment Inc., So So Def Productions and other defendants in a series of lawsuits asserting copyright infringement and other more